| I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $340.98M |
||||
| Company | Location | Date | Amt. (M) | Details |
| | ||||
| Achillion Pharmaceu- | New Haven, Conn. | 1/28 | $41 | Achillion raised $41M in a private round; investors were S.G. Capital Partners LLC, Bear Stearns Health Innoventures LP, Atlas Venture, Schroder Ventures, Advent International, Connecticut Innovations, KBL Healthcare, ING Furman Selz, Pacific Growth Equities, Oakwood Medical, Webster Financial and GE Capital |
| Alpha Innotech | San Leandro, | 1/14 | $8 | Alpha Innotech raised $8M in its first round of venture funding; BioAsia Investments LLC led the financing |
| BioVisioN | Hannover, | 1/28 | EUR15 | BioVisioN raised US$12.9M in a second-round financing led by Heidelberg Innovation; other investors were Nextech Venture and MPC Group, as well as Venture Vision, IMH and BioMed Venture |
| CXR Bio- | Dundee, | 1/23** | 4 (US | CXR raised US$5.7M in start-up funding from The Archangel investment group, the development agency Scottish Enterprise, and from the EU's European Regional Development Fund, among others |
| Cytos Bio- | Zurich, | 1/23 | $27 | Cytos Biotechnology completed its third-round financing, raising $27M; HBM BioVentures was lead investor; other investors were Equity4Life, LCF E. de Rothschild and Adamant Biomedical Investments, as well as Bank Julius Baer and the Cantonal Bank of Zurich |
| Diabetogen | London, | 1/25 | C$7.8 | Diabetogen completed a first round of equity investment totaling US$5M |
| Genoptix Inc. | San Diego | 1/28 | $17 | Genoptix raised $17M in a Series B financing led by Alliance Technology Ventures; other investors were Enterprise Partners, Lotus Bioscience Investment Holdings, Mitsubishi Corp., Mitsubishi International Corp., Tullis-Dickerson & Co. and U.S. Trust's Excelsior Venture Partners III LLC |
| Gryphon | South San | 1/28 | $26 | Gryphon raised $26M in a Series B financing led by the Sprout Group; other investors were Forward Ventures, BioAsia Investments LLC, S.R. One, and others |
| High Through- | Tucson, | 1/22 | $1.25 | High Throughput raised $1.25M in a Series A round of financing; investors were Solstice Capital, Tucson Ventures and Village Ventures |
| Hydro Med | Cranbury, | 1/25 | $7 | Hydro Med raised $7M in a private financing of Series A convertible preferred stock with institutional investors; Sanders Morris Harris acted as manager and Corporate Opportunities Fund was lead investor |
| Immunicon | Huntingdon | 1/30 | $28.8 | Immunicon raised about $28.8M through a private offering of convertible preferred equity; investors included Burrill & Co., Wheatley Partners, equity4Life, Canaan Partners, Foundation Medical Partners, Johnson & Johnson Development Corp., LHC Corp., TL Ventures, MDS Capital Corp., The Cleveland Clinic Foundation, Anthem Capital and MedCapital; UBS Warburg LLC was placement agent |
| Interface | Toronto | 1/28 | C$1 (US | Interface secured US$625,212 in funding from the Discovery District Biotech Fund |
| Medinox Inc. | San Diego | 1/11 | $13.8 | Medinox completed a $13.8M private offering of preferred stock; investors included China Development Industrial Bank of Taiwan, Chiao Tung Bank Co. Ltd., CIH Investment Capital Ltd., Core Pacific Venture Capital, Hua Hsia Investment Holding Co., IBT Venture Co., Taiwan Biotech Co. Ltd. and Prudence Venture Investment Corp. |
| Melacure | Uppsala, | 1/23** | SEK | The merged entity of Melacure and BioFactor Therapeutics AB received US$15.5M in equity funding from the companies' main shareholders |
| NeurogesX | San Carlos, | 1/23 | $23 | NeurogesX raised $23M in its Series B round of funding |
| OncoGenex | Vancouver, | 1/24 | C$3.6 | OncoGenex raised US$2.2M in a private financing led by BDC Venture Capital, with participation by Milestone Medica Corp., Qwest Emerging BiotechFund Ltd. and others |
| Proteom Ltd. | Cambridge, | 1/31 | 3 (US | Proteom completed a US$4.2M funding round, with Avlar BioVentures Ltd. and Technomark Medical Ventures participating |
| Quatrx Pharma- | Ann Arbor, | 1/23 | $10 | Quatrx raised $10M from Frazier & Co. and TL Ventures in a financing round |
| Renovis Inc. | South San | 1/9 | $34.3 | Renovis completed a $34.3M second round of financing; investors were HBM Bioventures AG, Applied Genomic Technology Capital Funds, Bioveda Capital, De Novo Ventures, International BM Biomedicine Holdings Ltd., Vertex Management & Double Helix and Yasuda Enterprise Development Co. Ltd. |
| Replicon | Danville, | 1/8 | $5 | Replicon received a first tranche of Series A financing from Tullis-Dickerson & Co. Inc. |
| Rib-X | New Haven, | 1/3 | $22 | Rib-X raised about $22M in its first round of financing; SR One Ltd./EuclidSR Partners and Oxford Bioscience Partners were lead investors; other investors were ABS Ventures, Axiom Ventures, Cardinal Partners, Connecticut Innovations and Zero Stage Capital |
| Switch Biotech | Munich, | 1/28 | US$1.9 | Switch raised additional funds, bringing the total of its third-round financing to US$18.4M |
| Symphogen | Copenhagen, | 1/22 | $15 | Symphogen raised $15M; Medicon Valley Capital was the lead investor, while Essex Woodlands Health Ventures, Novo A/S, Lonmodtagernes Dyrtidsfond, Vaekstfonden and Danske Bank also participated |
| Thuris Corp. | Irvine, | 1/30 | $3.8 | Thuris raised $3.8M in a private offering of preferred stock to an international group of investors and in a co-development and services agreement with the lead investor, Cephalon Inc. |
| Trigen Ltd. | London | 1/23** | 7.1 (US | Trigen raised US$10M in its first funding round led by HealthCap |
| II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $11M | ||||
| Company | Partner (Country) | Amt. (M) | Triggering Event | Details (Date) |
| | ||||
| Celera | Aventis | ND | Milestone payment | Celera received a milestone payment for the selection and advancement of individual Cathepsin S inhibitors for development as drugs for inflammation and autoimmune disease (1/10) |
| Consensus | Vertex Pharm- | ND | Milestone payment | Consensus achieved its first milestone in its collaboration to provide Vertex with substrates and structural analysis of the binding requirements for 10 protease targets (1/30) |
| Dynamis | Development | ND | Investment | The center agreed to make a multimillion-dollar research investment to optimize and perform preclinical studies on Dyn 12 (1/22) |
| Epimmune | Genencor | ND | Milestone payment | Epimmune received the milestone payment for identifying an EpiGene clinical product candidate for the lead program in their collaboration, a therapeutic hepatitis B vaccine (1/15) |
| Exelixis Inc. | Bayer AG | ND | Milestone payments | Exelixis received milestone payments for the delivery of additional novel targets and assays (1/17) |
| GPC Biotech | Aventis | ND | Milestone payment | GPC achieved the milestone in its osteoarthritis alliance with Aventis (1/10) |
| Protein | Nosan | $1 | Equity investment | Nosan made a $1M equity investment in Protein Sciences in connection with a 1999 agreement in which Nosan is the exclusive distributor of PSC's research antigens and insect cells in Japan (1/8) |
| Rigel Pharma- | Johnson & | ND | Milestone payment | J&J accepted two validated drug targets from Rigel, which will result in a milestone payment (1/31) |
| SemBioSys | AVAC Ltd. | C$2.4 | Repayable investment | SemBioSys will receive the investment to fully develop its technology platform to address the production of monoclonal antibodies (1/31) |
| Tissue | InforMax | $1.5 | Investment | InforMax invested $1.5M in TissueInformatics as part of their collaboration to integrate quantitative tissue data with genomic data (1/24) |
| Vertex | Eli Lilly | $5 | Milestone payment | Vertex received the payment due to the selection of LY570310 (VX-950) as a development candidate for hepatitis C virus infection (1/6) |
| V.I. Tech- | Precision | $2 | Milestone payment | V.I. Technologies earned a $2M contingent payment in connection with its divested plasma manufacturing operations in Melville, N.Y., and Precision's performance against certain financial milestones (1/23) |
| | ||||
| Notes: |
||||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
| * Denotes privately held company. |
||||
| ** Denotes the date the item ran in BioWorld International. |
||||
| ND = Not disclosed |
||||
| FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange |
||||
